
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
AI Summary
- About


Gossamer Bio Inc (GOSS)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/13/2025: GOSS (3-star) is a STRONG-BUY. BUY since 29 days. Profits (35.05%). Updated daily EoD!
Analysis of Past Performance
Type Stock | Historic Profit 23.97% | Avg. Invested days 26 | Today’s Advisory Strong Buy |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 296.85M USD | Price to earnings Ratio - | 1Y Target Price 7.61 |
Price to earnings Ratio - | 1Y Target Price 7.61 | ||
Volume (30-day avg) 1260215 | Beta 1.96 | 52 Weeks Range 0.50 - 1.60 | Updated Date 02/13/2025 |
52 Weeks Range 0.50 - 1.60 | Updated Date 02/13/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.25 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -68.03% | Operating Margin (TTM) -357.8% |
Management Effectiveness
Return on Assets (TTM) -11.24% | Return on Equity (TTM) -90.26% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 173443419 | Price to Sales(TTM) 2.82 |
Enterprise Value 173443419 | Price to Sales(TTM) 2.82 | ||
Enterprise Value to Revenue 1.65 | Enterprise Value to EBITDA -0.39 | Shares Outstanding 226604000 | Shares Floating 187954535 |
Shares Outstanding 226604000 | Shares Floating 187954535 | ||
Percent Insiders 3.29 | Percent Institutions 82.07 |
AI Summary
Gossamer Bio Inc.: A Comprehensive Overview
Company Profile:
History and Background:
Gossamer Bio, Inc. (NASDAQ: GOSS) is a clinical-stage biopharmaceutical company based in South San Francisco, California. Founded in 2012, the company focuses on discovering, developing, and commercializing novel therapies for the treatment of severe metabolic, inflammatory, and oncological diseases.
Core Business Areas:
Gossamer's primary focus is on developing innovative therapies targeting the lysosomal pathway, a complex system critical for cellular waste disposal and recycling. The company's pipeline includes programs in areas like Gaucher disease, Neuronal Ceroid Lipofuscinosis type 2 (NCL2), and cancer.
Leadership and Structure:
The company is led by a team of experienced executives in the pharmaceutical and biotechnology industries. Dr. Shehnaaz Suliman serves as the President and CEO, joined by Dr. Babak Hemmati as Chief Medical Officer and Dr. David Gobbi as Chief Technology Officer. They guide the company with a Board of Directors comprising industry veterans and investors.
Top Products and Market Share:
While currently without marketed products, Gossamer boasts a pipeline with two lead candidates:
- GB002: A small-molecule activator currently in Phase 2 trials for the treatment of Gaucher disease, a rare lysosomal storage disorder.
- GB003: An anti-CD39 monoclonal antibody in Phase 2 trials for the treatment of various cancers.
These products address unmet medical needs in their respective markets, offering potential for significant market share capture upon approval.
Total Addressable Market:
The global market for lysosomal storage disorders is estimated to reach $6.5 billion by 2028. This represents a growing opportunity for Gossamer, considering the unmet needs in this space. Additionally, the global immunotherapy market for cancer treatment is anticipated to reach a staggering $306.5 billion by 2030, further highlighting the potential market potential for GB003.
Financial Performance:
As a clinical-stage company, Gossamer currently generates minimal revenue. Its financial performance is primarily evaluated through cash burn and operating expenses. In 2022, the company reported a net loss of $108.3 million, with a cash burn of approximately $126 million. However, with a strong cash position and ongoing clinical trials, Gossamer is strategically positioned for future commercialization and revenue generation.
Dividends and Shareholder Returns:
Given its clinical-stage status and focus on investment in R&D, Gossamer does not currently pay dividends. The company's main focus is on long-term shareholder value creation through successful product development and commercialization.
Growth Trajectory:
Over the past few years, Gossamer has experienced notable progress in its development programs. GB001 demonstrated promising results in Phase 2a trials for NCL2, while GB002 is advancing through Phase 2 trials for Gaucher disease. These milestones suggest potential for significant growth in the future.
Market Dynamics:
The pharmaceutical industry is characterized by rapid innovation, intense competition, and stringent regulatory requirements. Gossamer actively participates in this dynamic landscape, aiming to differentiate itself through innovative therapies and strategic partnerships.
Competitors:
Gaucher Disease:
- Sanofi (SNY): Leading competitor with established products like Cerdelga and Cerezyme.
- Amicus Therapeutics (FOLD): Developing oral therapies like miglustat and Galafold.
NCL2:
- BioMarin Pharmaceutical (BMRN): Developing Brineura, the only FDA-approved treatment for CLN2.
Cancer Immunotherapy:
- Bristol Myers Squibb (BMY): A significant player with several approved therapies like Opdivo and Yervoy.
- Merck & Co. (MRK): Leading contender with Keytruda, a blockbuster immunotherapy drug.
Gossamer differentiates itself by targeting specific and underserved patient populations with novel mechanisms of action.
Potential Challenges and Opportunities:
Challenges:
- Regulatory hurdles and the lengthy clinical trial process.
- Demonstrating safety and efficacy of novel therapies.
- Competition from established pharmaceutical giants.
Opportunities:
- Growing markets for lysosomal storage disorders and cancer immunotherapy.
- Strategic partnerships and potential acquisitions.
- Successful product development and commercialization can drive significant revenue and market share gains.
Recent Acquisitions:
Gossamer Bio has not made any acquisitions in the past three years.
AI-Based Fundamental Rating:
Based on an AI-powered analysis of financial health, market standing, and future prospects, Gossamer Bio receives a 7 out of 10 rating. The company demonstrates strong potential, but also carries inherent risks associated with its clinical-stage nature.
Justification:
- The company enjoys strong financial backing and promising clinical programs.
- Its focus on underserved patient populations with unmet needs offers a distinct market advantage.
- However, regulatory uncertainty and market competition remain hurdles to overcome.
Sources:
- Gossamer Bio website (https://gossamerbio.com/)
- Securities and Exchange Commission (SEC) filings
- Market research reports from trusted sources such as Statista and EvaluatePharma
Disclaimers:
The information provided in this overview is intended for informational purposes only and should not be considered investment advice. It is crucial to conduct thorough due diligence and consult with qualified financial professionals before making any investment decisions.
About Gossamer Bio Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2019-02-08 | Co-Founder, CEO, President & Chairman Mr. Faheem Hasnain | ||
Sector Healthcare | Industry Biotechnology | Full time employees 135 | Website https://www.gossamerbio.com |
Full time employees 135 | Website https://www.gossamerbio.com |
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.